- Teva Pharmaceuticals (NYSE:TEVA) announces the availability of the first FDA-approved generic versions of Gilead Sciences' (NASDAQ:GILD) TRUVADA (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and ATRIPLA (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) tablets.
- These newly available generic medicines are indicated for the treatment of HIV-1 infection or HIV-1 pre-exposure prophylaxis when used alone or in combination with other anti-HIV-1 medicines.
- Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are expected to be available at $48.51 per tablet.
- Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets will be available at a price of $78.86/tablet.
- https://seekingalpha.com/news/3619365-teva-launches-first-generic-versions-of-hivminus-1-treatments-in-u-s
Friday, October 2, 2020
Teva launches first generic versions of HIV-1 treatments in U.S.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.